Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Exploratory Clinical Study of Trastuzumab Combined With Retlirafusp Alfa in Treating HER2 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure

NCT07817654 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07817654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07817654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Exploratory Clinical Study of Trastuzumab Combined With Retlirafusp Alfa in Treating HER2 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gc, gejc